Pan Tumor Rollover Study

Recruiting now · Phase 2

Conditions studied: Cancer

In brief

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Key facts

Study ID

NCT03899155

Run by

Bristol-Myers Squibb

People needed

1500

Starts

2019-08-09

Expected to finish

2029-08-25

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed Written Informed Consent.
• Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study.
• On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
• WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.

You may not qualify if…

• Participant is not eligible for study treatment per the Parent Study eligibility criteria.
• Participants not receiving clinical benefit as assessed by the Investigator.
• Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
• Other protocol-defined Inclusion/Exclusion Criteria apply

Where it is running

• Taipei Veterans General Hospital TPVGH — Taipei, Taiwan (enrolling)
• CHU Grenobles Alpes — La Tronche, France (enrolling)
• Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)
• Taichung Veterans General Hospital — Taichung, Taiwan (enrolling)
• Jiangsu Cancer Hospital — Nanjing, China (enrolling)
• Centre Jean Perrin — Clermont-Ferrand, France (enrolling)
• Harbin Medical University - Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
• Xiangya Hospital Central South University — Changsha, Hunan, China (enrolling)
• Tangdu Hospital of Fourth Military Medical University — Xi'an, Shaanxi, China (enrolling)
• Xian International Medical Center Hospital — Xi'an, Shan3XI, China (enrolling)
• Fudan University - Shanghai Cancer Center FUSCC — Shanghai, Shanghai Municipality, China (enrolling)
• Sir Run Run Shaw Hospital — Hangzhou, Zhejiang, China (enrolling)
• Cross Cancer Institute — Edmonton, Alberta, Canada (enrolling)
• FNHK Klinika onkologie a radioterapie — Hradec Králové, Czechia (enrolling)
• ICESP - Instituto do Cancer do Estado de Soo Paulo — São Paulo, São Paulo, Brazil (enrolling)
• Nanfang Hospital; Southern Medical University — Guangzhou, Guangdong, China (enrolling)
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
• Hospital Sao Lucas Da Pucrs — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
• Jilin University (JLU) - First Affiliated Hospital - Cancer Center — Changchun, Jilin, China (enrolling)
• Jilin Cancer Hospital — Changchun, Jilin, China (enrolling)
• Orlandi Oncologia — Providencia, Santiago Metropolitan, Chile (enrolling)
• Bradford Hill Centro de Investigacion Clinica — Santiago, Santiago Metropolitan, Chile (enrolling)
• Fundacion Arturo Lopez Perez — Santiago, Santiago Metropolitan, Chile (enrolling)
• Irmandade da Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
• Pole Biologie Pathologie Genetique - CHU de Lille — Lille, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.